| Year |
Citation |
Score |
| 2024 |
Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, ... ... Bazhenova L, et al. Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38277235 DOI: 10.1158/1078-0432.CCR-23-0251 |
0.305 |
|
| 2023 |
Wang M, Slatter S, Sussell J, Lin CW, Ogale S, Datta D, Butte AJ, Bazhenova L, Rudrapatna VA. ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study. Targeted Oncology. PMID 37341856 DOI: 10.1007/s11523-023-00973-7 |
0.407 |
|
| 2023 |
Yun KM, Bazhenova L. Metastatic -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan. Bmj Case Reports. 16. PMID 37156567 DOI: 10.1136/bcr-2022-253260 |
0.413 |
|
| 2022 |
Yang JC, Zhou C, Jänne PA, Ramalingam SS, Kim TM, Riely GJ, Spira AI, Piotrowska Z, Mekhail T, Garcia Campelo MR, Felip E, Bazhenova L, Jin S, Kaur M, Diderichsen PM, et al. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for exon 20 insertion-positive non-small cell lung cancer. Expert Review of Anticancer Therapy. 1-12. PMID 36537204 DOI: 10.1080/14737140.2023.2157815 |
0.395 |
|
| 2022 |
Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC, Hong D, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Targeted Oncology. PMID 36459255 DOI: 10.1007/s11523-022-00931-9 |
0.388 |
|
| 2022 |
Bazhenova L, Kish J, Cai B, Caro N, Feinberg B. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer. Cancer Treatment and Research Communications. 33: 100637. PMID 36162323 DOI: 10.1016/j.ctarc.2022.100637 |
0.337 |
|
| 2022 |
Girard N, Minchom A, Ou SI, Gadgeel SM, Trigo J, Viteri S, Bauml JM, Londhe A, Mahadevia P, Bazhenova L. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Clinical Lung Cancer. PMID 36085282 DOI: 10.1016/j.cllc.2022.07.007 |
0.302 |
|
| 2022 |
Giustini NP, Patel SP, Myall NJ, Fernando do Prado Moura J, Kulkarni A, Chao RC, Wakelee H, Bazhenova L. Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on : Case Series and Literature Review of Treatment. Jco Precision Oncology. 6: e2100551. PMID 35952324 DOI: 10.1200/PO.21.00551 |
0.334 |
|
| 2022 |
Bauer T, Cho BC, Heist R, Bazhenova L, Werner T, Goel S, Kim DW, Adkins D, Carvajal RD, Alva A, Eaton K, Wang J, Liu Y, Yan X, Christensen J, et al. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. Investigational New Drugs. PMID 35767205 DOI: 10.1007/s10637-022-01274-y |
0.331 |
|
| 2022 |
Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation. The New England Journal of Medicine. PMID 35658005 DOI: 10.1056/NEJMoa2204619 |
0.327 |
|
| 2022 |
Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer (Amsterdam, Netherlands). 168: 74-82. PMID 35597172 DOI: 10.1016/j.lungcan.2022.03.005 |
0.423 |
|
| 2022 |
Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, ... ... Bazhenova L, et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discovery. PMID 35404393 DOI: 10.1158/2159-8290.CD-21-1615 |
0.404 |
|
| 2022 |
Yu L, Bazhenova L, Gold K, Tran L, Hilburn V, Vu P, Patel SP. Clinicopathologic and molecular characteristics of -mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Translational Lung Cancer Research. 11: 452-461. PMID 35399568 DOI: 10.21037/tlcr-21-665 |
0.39 |
|
| 2022 |
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, et al. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Medicine. PMID 35307972 DOI: 10.1002/cam4.4635 |
0.393 |
|
| 2022 |
Yun KM, Bazhenova LA. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC. Cancer Management and Research. 14: 843-850. PMID 35250311 DOI: 10.2147/CMAR.S283199 |
0.382 |
|
| 2022 |
Ou SI, Jänne PA, Leal TA, Rybkin II, Sabari JK, Barve MA, Bazhenova LA, Johnson ML, Velastegui KL, Cilliers C, Christensen JG, Yan X, Chao RC, Papadopoulos KP. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors (KRYSTAL-1). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102752. PMID 35167329 DOI: 10.1200/JCO.21.02752 |
0.381 |
|
| 2021 |
Yang JC, Reckamp KL, Kim YC, Novello S, Smit EF, Lee JS, Su WC, Akerley WL, Blakely CM, Groen HJM, Bazhenova L, Carcereny Costa E, Chiari R, Hsia TC, Golsorkhi T, et al. Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With -Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study. Jto Clinical and Research Reports. 2: 100114. PMID 34589984 DOI: 10.1016/j.jtocrr.2020.100114 |
0.335 |
|
| 2021 |
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, et al. Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer. The New England Journal of Medicine. PMID 34534430 DOI: 10.1056/NEJMoa2112431 |
0.402 |
|
| 2021 |
Kozono DE, Stinchcombe TE, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Chen X, Sun Z, Nuthalapati I, Rosenwinkel L, et al. Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 159: 56-65. PMID 34311345 DOI: 10.1016/j.lungcan.2021.06.028 |
0.404 |
|
| 2021 |
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, et al. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 34264316 DOI: 10.1001/jamaoncol.2021.2209 |
0.437 |
|
| 2021 |
Schokrpur S, Hilburn V, Giustini N, Bazhenova L. An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. Expert Opinion On Pharmacotherapy. PMID 34225542 DOI: 10.1080/14656566.2021.1948014 |
0.38 |
|
| 2021 |
Garon EB, Spira AI, Johnson M, Bazhenova L, Leach J, Cummings AL, Candia A, Coffman RL, Janatpour MJ, Janssen R, Gamelin E, Chow LQM. A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34108179 DOI: 10.1158/1078-0432.CCR-21-0263 |
0.347 |
|
| 2021 |
Subbiah V, Gainor JF, Oxnard GR, Tan DSW, Owen DH, Cho BC, Loong HHF, McCoach CE, Weiss J, Kim YJ, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34088726 DOI: 10.1158/1078-0432.CCR-21-0800 |
0.4 |
|
| 2021 |
Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discovery. PMID 33632775 DOI: 10.1158/2159-8290.CD-20-1598 |
0.399 |
|
| 2020 |
Bazhenova L, Urbanic J, Onaitis M. Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance? The Journal of Thoracic and Cardiovascular Surgery. PMID 33581906 DOI: 10.1016/J.Jtcvs.2020.06.109 |
0.409 |
|
| 2020 |
Chih-Hsin Yang J, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, ... ... Bazhenova L, et al. Safety, Efficacy and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients with EGFR-mutated Advanced NSCLC: a Multicenter, Open-label, Phase I Trial. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32916310 DOI: 10.1016/J.Jtho.2020.09.001 |
0.467 |
|
| 2020 |
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, ... ... Bazhenova L, et al. Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine. 383: 813-824. PMID 32846060 DOI: 10.1056/Nejmoa2005653 |
0.5 |
|
| 2020 |
Giustini NP, Jeong AR, Buturla J, Bazhenova L. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy. Clinics in Chest Medicine. 41: 223-235. PMID 32402358 DOI: 10.1016/J.Ccm.2020.02.003 |
0.473 |
|
| 2020 |
Giustini NP, Bazhenova L. ROS1-rearranged Non-small Cell Lung Cancer. Thoracic Surgery Clinics. 30: 147-156. PMID 32327173 DOI: 10.1016/J.Thorsurg.2020.01.007 |
0.484 |
|
| 2020 |
Doebele RC, Lin JJ, Nagasaka M, Zhu VW, Gabrail NY, Bazhenova L, Anderson PM, Solomon BJ, Dudek AZ, Pippas AW, Shirinian M, Baik CS, Stopatschinskaja S, Camidge DR, Cho BC, et al. TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps9637 |
0.339 |
|
| 2020 |
Hong DS, Sen S, Park H, Heist RS, Gadgeel SM, Zimmerman ZF, Bazhenova L. A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps3663 |
0.366 |
|
| 2020 |
Nan X, Gabbai-Saldate P, Patel SP, Bazhenova L, Mitchell WM, Gold KA. Safety and outcomes of immunotherapy re-challenge in lung cancer. Journal of Clinical Oncology. 38: e19355-e19355. DOI: 10.1200/Jco.2020.38.15_Suppl.E19355 |
0.404 |
|
| 2020 |
Solomon BM, Callejo A, Bar J, Berchem GJ, Bazhenova L, Saintigny P, Raymond E, Girard N, Sulaiman R, Prouse B, Bresson C, Wunder F, Lee JJ, Raynaud J, Rubin E, et al. SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates. Journal of Clinical Oncology. 38: 9581-9581. DOI: 10.1200/Jco.2020.38.15_Suppl.9581 |
0.437 |
|
| 2020 |
Morgensztern D, Waqar SN, Bazhenova L, McDermott L, Hutchins J, Taylor DH, Robinson FL, Dowdell AK, Piening B, Harb WA, Pennell NA, Cohen RB. Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab. Journal of Clinical Oncology. 38: 9546-9546. DOI: 10.1200/Jco.2020.38.15_Suppl.9546 |
0.456 |
|
| 2020 |
Subbiah V, Gainor JF, Oxnard GR, Tan DS, Owen DH, Cho BC, Loong HHF, McCoach CE, Weiss J, Kim Y, Bazhenova L, Park K, Daga H, Besse B, Gautschi O, et al. Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. Journal of Clinical Oncology. 38: 9516-9516. DOI: 10.1200/Jco.2020.38.15_Suppl.9516 |
0.507 |
|
| 2020 |
Rolfo CD, Braud FGD, Doebele RC, Drilon AE, Siena S, Patel M, Cho BC, Liu SV, Ahn M, Chiu C, Farago AF, Goto K, Lee J, Bazhenova L, John T, et al. Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. Journal of Clinical Oncology. 38: 3605-3605. DOI: 10.1200/Jco.2020.38.15_Suppl.3605 |
0.362 |
|
| 2020 |
Morgensztern D, Bazhenova L, Waqar SN, McDermott L, Hutchins J, Harb W, Pennell N, Cohen RB. Abstract B31: Viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-B31 |
0.472 |
|
| 2020 |
Bazhenova L, Jiao X, Lokker A, Snider J, Castellanos E, Nanda S, Fisher V, Zong J, Keating K, Fellous M. Abstract 09: Cancers with NTRK gene fusions: Molecular characteristics and prognosis Clinical Cancer Research. 26: 9-9. DOI: 10.1158/1557-3265.Advprecmed20-09 |
0.388 |
|
| 2020 |
Patel M, Siena S, Demetri G, Doebele R, Chae Y, Conkling P, Garrido-Laguna I, Longo F, Rolfo C, Sigal D, Drilon A, Liu S, Goto K, Bazhenova L, Lonardi S, et al. O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001) Annals of Oncology. 31: 232-233. DOI: 10.1016/J.Annonc.2020.04.056 |
0.327 |
|
| 2019 |
Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, et al. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii48-ii49. PMID 32131246 DOI: 10.1093/Annonc/Mdz063.011 |
0.51 |
|
| 2019 |
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. PMID 31838007 DOI: 10.1016/S1470-2045(19)30691-6 |
0.377 |
|
| 2019 |
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, ... ... Bazhenova L, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548343 DOI: 10.1158/1078-0432.Ccr-19-1667 |
0.471 |
|
| 2019 |
Shishido SN, Carlsson A, Nieva J, Bethel K, Hicks JB, Bazhenova L, Kuhn P. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. Journal of Translational Medicine. 17: 294. PMID 31462312 DOI: 10.1186/S12967-019-2035-8 |
0.474 |
|
| 2019 |
Stinchcombe TE, Jänne PA, Wang X, Bertino EM, Weiss J, Bazhenova L, Gu L, Lau C, Paweletz C, Jaslowski A, Gerstner GJ, Baggstrom MQ, Graziano S, Bearden J, Vokes EE. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 31393548 DOI: 10.1001/Jamaoncol.2019.1847 |
0.529 |
|
| 2019 |
Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali SM, Bazhenova L, Schrock AB, Meiler J, Lovly CM. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele specific manner dependent on the original EGFR activating mutation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30796031 DOI: 10.1158/1078-0432.Ccr-18-3829 |
0.364 |
|
| 2019 |
Villanueva N, Son K, Yeh S, Jain S, Eng E, Lloyd K, Huang L, Mohanlal RW, Bazhenova L. A phase I trial combining plinabulin and nivolumab for metastatic NSCLC: Trial in progress. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.8_Suppl.Tps128 |
0.372 |
|
| 2019 |
Morgensztern D, Bazhenova L, Waqar SN, McDermott L, Hutchins J, Harb WA, Velcheti V, Cohen RB. Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 37: 101-101. DOI: 10.1200/Jco.2019.37.8_Suppl.101 |
0.44 |
|
| 2019 |
Villanueva N, Son K, Hattangadi JA, Simpson DR, Sanghvi PR, Patel SP, Husain H, Urbanic JJ, Gold KA, Mitchell WM, Bazhenova L. Upfront EGFR TKI with or without brain radiotherapy (RT) in EGFR-driven non-small cell lung cancer (NSCLC) with brain metastases. Journal of Clinical Oncology. 37: e20614-e20614. DOI: 10.1200/Jco.2019.37.15_Suppl.E20614 |
0.457 |
|
| 2019 |
Morgensztern D, Sanborn RE, Bazhenova L, Waqar SN, McDermott L, Hutchins J, Rimm DL, Raez LE, Langer CJ, Cohen RB. Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure. Journal of Clinical Oncology. 37: 9109-9109. DOI: 10.1200/Jco.2019.37.15_Suppl.9109 |
0.453 |
|
| 2019 |
Bazhenova L, Redman MW, Gettinger SN, Hirsch FR, Mack PC, Schwartz LH, Gandara DR, Bradley JD, Stinchcombe T, Leighl NB, Ramalingam SS, Tavernier SS, Minichiello K, Kelly K, Papadimitrakopoulou V, et al. A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). Journal of Clinical Oncology. 37: 9014-9014. DOI: 10.1200/Jco.2019.37.15_Suppl.9014 |
0.451 |
|
| 2019 |
Janne PA, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Horn L, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West H, Vincent S, Zhu J, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Journal of Clinical Oncology. 37: 9007-9007. DOI: 10.1200/Jco.2019.37.15_Suppl.9007 |
0.414 |
|
| 2019 |
Kozono DE, Stinchcombe T, Salama JK, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Hu B, Nuthalapati S, Luo Y, Vokes EE. Veliparib (Vel) in combination with chemoradiotherapy (CRT) of carboplatin/paclitaxel (C/P) plus radiation in patients (pts) with stage III non-small cell lung cancer (NSCLC) (M14-360/AFT-07). Journal of Clinical Oncology. 37: 8510-8510. DOI: 10.1200/Jco.2019.37.15_Suppl.8510 |
0.362 |
|
| 2019 |
Solomon B, Felip E, Bar J, Berchem G, Bazhenova L, Saintigny P, Girard N, Sulaiman R, Bresson C, Wunder F, Lee JJ, Raynaud J, Rubin E, Young B, Lazar V, et al. Abstract CT223: Survival Prolongation by Rationale INnovative Genomics (SPRING): An international WIN Consortium Phase I/II proof-of-concept study to explore the safety and efficacy of a tri-therapy approach using avelumab, palbociclib and axitinib in advanced/metastatic non-small cell lung cancer (NSCLC) with integrated genomic and transcriptomic correlates Clinical Trials. DOI: 10.1158/1538-7445.Sabcs18-Ct223 |
0.442 |
|
| 2019 |
Garon E, Spira AI, Johnson M, Bazhenova L, Leach J, Candia A, Coffman R, Janatpour M, Gamelin E, Janssen R, Chow LQ. Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct224 |
0.43 |
|
| 2019 |
Doebele R, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, et al. Abstract CT131: Entrectinib inNTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct131 |
0.531 |
|
| 2019 |
Zhang Y, Brown BP, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Abstract 930: On-target resistance to mutant selective EGFR inhibitors develops in an allele-specific manner dependent on the original EGFR activating mutation Cancer Research. 79: 930-930. DOI: 10.1158/1538-7445.Am2019-930 |
0.398 |
|
| 2019 |
Jänne PA, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Tsao A, Patel J, Gadgeel S, Bazhenova L, Zhu VW, West H, Vincent S, Zhu J, et al. Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz338.077 |
0.401 |
|
| 2019 |
Riely G, Neal J, Camidge D, Spira A, Piotrowska Z, Horn L, Costa D, Tsao A, Patel J, Gadgeel S, Bazhenova L, Zhu V, West H, Vincent S, Zhu J, et al. P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions Journal of Thoracic Oncology. 14: S412-S413. DOI: 10.1016/J.Jtho.2019.08.842 |
0.388 |
|
| 2019 |
Bazhenova L, Redman M, Gettinger S, Hirsch FR, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, et al. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.423 |
0.476 |
|
| 2019 |
Mohanlal R, Sun Y, Kloecker G, Feinstein T, Shi Y, Han B, Bazhenova L, Du L, Huang L. P2.01-23 DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1367 |
0.314 |
|
| 2019 |
Kim H, Vu P, Harrow K, Liang C, Selvaggi G, Weihe E, Mitchell W, Bazhenova L, Patel S. P1.14-57 Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1208 |
0.468 |
|
| 2019 |
Drilon A, Oxnard G, Wirth L, Besse B, Gautschi O, Tan SWD, Loong H, Bauer T, Kim YJ, Horiike A, Park K, Shah M, McCoach C, Bazhenova L, Seto T, et al. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.059 |
0.477 |
|
| 2018 |
Stinchcombe TE, Janne PA, Wang X, Bertino EM, Weiss JM, Bazhenova L, Gu L, Lau CJ, Paweletz CP, Jaslowski AJ, Gerstner GJ, Baggstrom MQ, Graziano SL, Bearden J, Vokes EE. A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii522. PMID 32137355 DOI: 10.1093/Annonc/Mdy292.066 |
0.532 |
|
| 2018 |
Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. PMID 30512189 DOI: 10.1002/Cncr.31891 |
0.456 |
|
| 2018 |
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, et al. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. Cancer Discovery. PMID 30487236 DOI: 10.1158/2159-8290.Cd-18-0839 |
0.475 |
|
| 2018 |
Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Therapeutic Advances in Respiratory Disease. 12: 1753466618794133. PMID 30215300 DOI: 10.1177/1753466618794133 |
0.416 |
|
| 2018 |
Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. The Oncologist. PMID 29769383 DOI: 10.1634/Theoncologist.2017-0375 |
0.307 |
|
| 2018 |
Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017775841. PMID 29768119 DOI: 10.1200/JCO.2017.77.5841 |
0.361 |
|
| 2018 |
Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology, Biology, Physics. PMID 29487024 DOI: 10.1016/J.Ijrobp.2018.01.046 |
0.463 |
|
| 2018 |
Cho DC, Mahipal A, Dowlati A, Chow WA, Segal NH, Chung KY, Schneider BJ, Nemunaitis JJ, Razak ARA, Tsai FY, Balmanoukian AS, Bazhenova L, Xiao F, Angra N, Abdullah SE, et al. Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). Journal of Clinical Oncology. 36: 8517-8517. DOI: 10.1200/Jco.2018.36.15_Suppl.8517 |
0.425 |
|
| 2018 |
Demetri GD, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, Kim ES, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy483.003 |
0.315 |
|
| 2018 |
Lu S, Camidge R, Yang C, Zhou J, Guo R, Chiu C, Chang G, Shiah H, Chen Y, Wang C, Berz D, Su W, Yang N, Wang Z, Fang J, ... ... Bazhenova L, et al. P1.01-62 The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients Journal of Thoracic Oncology. 13: S485. DOI: 10.1016/J.Jtho.2018.08.618 |
0.513 |
|
| 2018 |
Oxnard G, Subbiah V, Park K, Bauer T, Wirth L, Velcheti V, Shah M, Besse B, Boni V, Reckamp K, Loong H, Bazhenova L, Solomon B, Tan D, Patel J, et al. OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S349-S350. DOI: 10.1016/J.Jtho.2018.08.304 |
0.486 |
|
| 2017 |
Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two Phase II trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29293889 DOI: 10.1093/Annonc/Mdx820 |
0.494 |
|
| 2017 |
Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. PMID 29169877 DOI: 10.1016/S1470-2045(17)30694-0 |
0.52 |
|
| 2017 |
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Molecular Cancer Therapeutics. PMID 28835386 DOI: 10.1158/1535-7163.Mct-17-0386 |
0.348 |
|
| 2017 |
Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Research. PMID 28807936 DOI: 10.1158/0008-5472.Can-17-0885 |
0.436 |
|
| 2017 |
Schwaederle M, Patel SP, Husain H, Ikeda M, Lanman R, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of genomic assessment of blood-derived circulating tumor DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28539465 DOI: 10.1158/1078-0432.Ccr-16-2497 |
0.469 |
|
| 2017 |
Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Makani S, Magaña M, Bazhenova L, et al. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 28446544 DOI: 10.1158/1055-9965.Epi-17-0120 |
0.428 |
|
| 2017 |
Mohanlal RW, LLoyd K, Huang L, Bazhenova L. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. Journal of Clinical Oncology. 35: 139-139. DOI: 10.1200/Jco.2017.35.7_Suppl.139 |
0.369 |
|
| 2017 |
Bazhenova L, Gettinger SN, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Haney J, Rivera VM, Kerstein D, Camidge DR. Brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial. Journal of Clinical Oncology. 35: e20682-e20682. DOI: 10.1200/Jco.2017.35.15_Suppl.E20682 |
0.443 |
|
| 2017 |
Goodman A, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller VA, Stephens P, Kurzrock R. Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers. Journal of Clinical Oncology. 35: e14508-e14508. DOI: 10.1200/Jco.2017.35.15_Suppl.E14508 |
0.373 |
|
| 2017 |
Khagi Y, Goodman A, Daniels GA, Patel SP, Bazhenova L, Kurzrock R. Total number of circulating tumor DNA (ctDNA) genomic alterations and outcome after checkpoint inhibitor-based immunotherapy. Journal of Clinical Oncology. 35: e14504-e14504. DOI: 10.1200/Jco.2017.35.15_Suppl.E14504 |
0.432 |
|
| 2017 |
Lanman TA, Kesari S, Patel SP, Bazhenova L, Parker BA, Daniels GA, Fanta PT, Plaxe SC, Schwaederle MC, Kurzrock R, Piccioni DE. Comparison of tissue DNA to circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 35: e13546-e13546. DOI: 10.1200/Jco.2017.35.15_Suppl.E13546 |
0.333 |
|
| 2017 |
Bazhenova L, Hodgson JG, Langer CJ, Simon GR, Gettinger SN, Ou SI, Reckamp KL, West HJ, Chiappori A, Koh HA, Molina JR, Shaw AT, Patel JD, Favaro JP, Haney J, et al. Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status. Journal of Clinical Oncology. 35: 9065-9065. DOI: 10.1200/Jco.2017.35.15_Suppl.9065 |
0.361 |
|
| 2017 |
Kozono DE, Salama JK, Stinchcombe T, Bogart J, Petty WJ, Guarino MJ, Bazhenova L, Larner JM, Weiss J, DiPetrillo TA, Feigenberg SJ, Xu T, Hu B, Nuthalapati S, Rosenwinkel L, et al. Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P): Based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 35: 8546-8546. DOI: 10.1200/Jco.2017.35.15_Suppl.8546 |
0.448 |
|
| 2017 |
Schwaederle MC, Chattopadhyay R, Kato S, Fanta PT, Banks K, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic alterations in 670 patients with diverse cancers analyzed by next-generation sequencing (NGS) of circulating tumor DNA (ctDNA). Journal of Clinical Oncology. 35: 11593-11593. DOI: 10.1200/Jco.2017.35.15_Suppl.11593 |
0.454 |
|
| 2017 |
Bazhenova L, Gold PJ, Harvey RD, Spira AI, Nemunaitis J, Baranda JC, Gadgeel S. Abstract CT032: A Phase 1b study of PEGPH20 plus pembrolizumab in patients with selected hyaluronan-high solid tumors Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct032 |
0.486 |
|
| 2017 |
Mason JM, Ciccarella A, Marx-Rubiner L, Bazhenova L, Newton PK, Bethel K, Nieva JJ, Kuhn P. Abstract 4532: Adrenal metastases in lung cancer: Clinical implications of a mathematical model Cancer Research. 77: 4532-4532. DOI: 10.1158/1538-7445.Am2017-4532 |
0.418 |
|
| 2017 |
Shishido SN, Bazhenova L, Carlsson A, Hicks J, Kuhn P. Abstract 1712: Detection of circulating tumor cells in stage IV non-small cell lung cancer Cancer Research. 77: 1712-1712. DOI: 10.1158/1538-7445.Am2017-1712 |
0.463 |
|
| 2017 |
Park K, Jänne PA, Yu C, Bazhenova L, Paz-Ares L, Baek E, Han O, Hong KY, Kwon H, Kim Y, Kim SR. 412OA global phase II study of olmutinib (HM61713) in patients with T790M-positive NSCLC after failure of first-line EGFR-TKI Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx671.001 |
0.407 |
|
| 2017 |
Drilon AE, Liu S, Doebele R, Rodriguez C, Fakih M, Reckamp KL, Bazhenova L, Cho BC, Kowack E, Oliver J, Multani P, Ahn M. LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx440.012 |
0.39 |
|
| 2017 |
Mitsudomi T, Ahn M, Bazhenova L, Blackhall F, Hida T, Tarruella MM, Vowler SL, Laus G, Jänne PA, Yang JC. 1348POverall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx380.050 |
0.534 |
|
| 2017 |
Yang J, Reckamp K, Kim Y, Novello S, Smit E, Lee J, Su W, Akerley W, Blakely C, Bazhenova L, Chiari R, Hsia T, Golsorkhi T, Despain D, Shih D, et al. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S2397. DOI: 10.1016/J.Jtho.2017.11.013 |
0.505 |
|
| 2017 |
Bazhenova L, Tran R, Grilley-Olson J, Sharma N, Combest A, Bobe I, Osada A, Takahasi K, Balkissoon J, Camp A, Masada A, Reitsma D, Subbiah V. P1.03-044 Exploratory Analysis of Lung Cancer Patients in a Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.848 |
0.449 |
|
| 2017 |
Camidge D, Ahn M, Reckamp K, West H, Huber R, Langer C, Bazhenova L, Leighl N, Reichmann W, Kerstein D, Kim D. P1.01-004 Hypertension With Brigatinib: Experience in ALTA, a Randomized Phase 2 Trial in Crizotinib-Refractory ALK+ NSCLC Journal of Thoracic Oncology. 12: S1893. DOI: 10.1016/J.Jtho.2017.09.658 |
0.353 |
|
| 2017 |
Stinchcombe T, Kozono D, Salama J, Bogart J, Petty W, Guarino M, Bazhenova L, Larner J, Weiss J, Dipetrillo T, Feigenberg S, Xu T, Hu B, Nuthalapati S, Rosenwinkel L, et al. MA 17.07 Veliparib in Combination with Paclitaxel/Carboplatin (P/C)-Based Chemoradiotherapy (CRT) in Patients with Stage III NSCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.614 |
0.382 |
|
| 2017 |
Herbst R, Redman M, Gandara DR, Hirsch FR, Mack P, Borghaei H, Langer C, Wade J, Engelman J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, ... Bazhenova L, et al. OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.412 |
0.376 |
|
| 2017 |
Goss G, Tsai C, Shepherd F, Ahn M, Bazhenova L, Crinò L, Marinis FD, Felip E, Morabito A, Hodge R, Cantarini M, Mitsudomi T, Jänne P, Yang JC. MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.514 |
0.398 |
|
| 2017 |
Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch FR, Mack P, Borghaei H, Langer C, Wade J, Edelman M, Albain K, Lara P, Aggarwal C, Socinski M, Gettinger S, Bazhenova L, et al. MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.513 |
0.355 |
|
| 2017 |
Gettinger S, Kim D, Tiseo M, Langer C, Ahn M, Shaw A, Huber R, Hochmair M, Kim S, Bazhenova L, Gold K, Ou S, West H, Reichmann W, Haney J, et al. OA08.06 Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials Journal of Thoracic Oncology. 12: S273-S274. DOI: 10.1016/J.Jtho.2016.11.271 |
0.4 |
|
| 2017 |
Baumgart M, Bazhenova L, Haggstrom D, Baranda J, Belani C. PUB031 PRIMAL: A Phase 1b Study of PEGPH20 plus Docetaxel in Patients with Previously Treated Hyaluronan (HA)-High Advanced NSCLC Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.2001 |
0.398 |
|
| 2017 |
Gold P, Harvey RD, Spira A, Bazhenova L, Nemunaitis J, Baranda J, Gadgeel S. P3.02c-011 A Phase 1b Open-Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan-High Solid Tumors:Topic: Targeted Therapy Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1806 |
0.331 |
|
| 2017 |
Bazhenova L, Kim D, Cavanna L, Han J, Lee JS, Kim H, Cho BC, Schreeder M, Masood A, Rybkin I, Johnson M, Boleman B, Batus M, Rodriguez E, Hong D, et al. P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET Journal of Thoracic Oncology. 12: S1080-S1081. DOI: 10.1016/J.Jtho.2016.11.1510 |
0.448 |
|
| 2017 |
Werner T, Heist R, Carvajal R, Adkins D, Alva A, Goel S, Hong D, Bazhenova L, Saleh M, Siegel R, Kyriakopoulos C, Blakely C, Eaton K, Lauer R, Wang D, et al. P2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors Journal of Thoracic Oncology. 12: S1068-S1069. DOI: 10.1016/J.Jtho.2016.11.1494 |
0.393 |
|
| 2016 |
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. The Lancet. Oncology. PMID 27836716 DOI: 10.1016/S1470-2045(16)30392-8 |
0.433 |
|
| 2016 |
Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. The Lancet. Oncology. PMID 27751847 DOI: 10.1016/S1470-2045(16)30508-3 |
0.464 |
|
| 2016 |
Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, et al. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer. PMID 27686971 DOI: 10.1016/J.Cllc.2016.07.007 |
0.443 |
|
| 2016 |
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 255-64. PMID 26957612 DOI: 10.6004/Jnccn.2016.0031 |
0.4 |
|
| 2016 |
Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Molecular Cancer Therapeutics. PMID 26873727 DOI: 10.1158/1535-7163.MCT-15-0795 |
0.376 |
|
| 2016 |
Yang JC, Popat S, Novello S, Groen HJ, Perol M, Felip E, Griesinger F, Reckamp KL, Lee J, Smit EF, Blakely CM, Akerley WL, Kim Y, Bazhenova L, Califano R, et al. TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. Journal of Clinical Oncology. 34: TPS9106-TPS9106. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9106 |
0.489 |
|
| 2016 |
Schwaederle MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of liquid biopsies to assess circulating tumor DNA in patients with lung adenocarcinoma. Journal of Clinical Oncology. 34: e23097-e23097. DOI: 10.1200/Jco.2016.34.15_Suppl.E23097 |
0.426 |
|
| 2016 |
Bazhenova L, Das S, Patel SP, Arnold L, Singh VM. CtDNA assay to detect EGFR mutations and mechanisms of resistance to EGFR tyrosine kinase inhibitors. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E23042 |
0.402 |
|
| 2016 |
Mohanlal R, Aren OR, Polikoff J, Reich SD, Mikrut W, Huang L, Bazhenova L. The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.E20595 |
0.41 |
|
| 2016 |
Hirsch FR, Redman MW, Herbst RS, Kim ES, Semrad TJ, Bazhenova L, Masters GA, Oettel KR, Guaglianone P, Reynolds CM, Karnad AB, Arnold SM, Varella-Garcia M, Moon J, Mack PC, et al. Biomarker-enriched efficacy of cetuximab-based therapy: Squamous subset analysis from S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC. Journal of Clinical Oncology. 34: 9090-9090. DOI: 10.1200/Jco.2016.34.15_Suppl.9090 |
0.404 |
|
| 2016 |
Papadimitrakopoulou V, Redman M, Gandara DR, Hirsch FR, Mack PC, Borghaei H, Langer CJ, Engelman JA, Edelman MJ, Albain KS, Lara P, Aggarwal C, Socinski MA, Gettinger SN, Bazhenova L, et al. Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. Journal of Clinical Oncology. 34: 9088-9088. DOI: 10.1200/Jco.2016.34.15_Suppl.9088 |
0.394 |
|
| 2016 |
Semrad TJ, Redman MW, Herbst RS, Kim ES, Bazhenova L, Masters GA, Oettel KR, Guaglianone P, Reynolds CM, Karnad AB, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, et al. Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9082-9082. DOI: 10.1200/Jco.2016.34.15_Suppl.9082 |
0.479 |
|
| 2016 |
Gettinger SN, Zhang S, Hodgson JG, Bazhenova L, Burgers S, Kim D, Tan DS, Koh HA, Ho JCM, Viteri Ramirez S, Shaw AT, Weiss GJ, Langer CJ, Huber RM, Ahn M, et al. Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. Journal of Clinical Oncology. 34: 9060-9060. DOI: 10.1200/Jco.2016.34.15_Suppl.9060 |
0.389 |
|
| 2016 |
Langer CJ, Gettinger SN, Bazhenova L, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Dorer DJ, Rivera VM, Haluska FG, Kerstein D, Camidge DR. Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results. Journal of Clinical Oncology. 34: 9057-9057. DOI: 10.1200/Jco.2016.34.15_Suppl.9057 |
0.438 |
|
| 2016 |
Boffa DJ, Nieva JJ, Bazhenova L, Krupa R, Lu D, Graf R, Louw J, Dugan L, Jendrisak A, Salazar M, Makani S, Magana M, Orr S, Bethel K, Wang Y, et al. Programmed cell death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients (Pts) with lung cancer in a prospective, multicenter cohort. Journal of Clinical Oncology. 34: 8524-8524. DOI: 10.1200/Jco.2016.34.15_Suppl.8524 |
0.468 |
|
| 2016 |
Patel MR, Fakih M, Olszanski AJ, Lockhart AC, Drilon AE, Fu S, Bazhenova L, Patel R, Oliver JW, Multani PS, Wang D. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology. 34: 2574-2574. DOI: 10.1200/Jco.2016.34.15_Suppl.2574 |
0.398 |
|
| 2016 |
Faiq N, Patel SP, Bazhenova L, Parker BA, Plaxe SC, Kurzrock R, Kesari S, Piccioni DE. Characterization of cell-free circulating tumor DNA in patients with brain metastases. Journal of Clinical Oncology. 34: 2023-2023. DOI: 10.1200/Jco.2016.34.15_Suppl.2023 |
0.352 |
|
| 2016 |
Blayney DW, Bazhenova L, Lloyd GK, Huang L, Mohanlal R. Plinabulin, a Novel Small Molecule That Ameliorates Chemotherapy-Induced Neutropenia, Is Administered on the Same Day of Chemotherapy and Has Anticancer Efficacy Blood. 128: 2508-2508. DOI: 10.1182/Blood.V128.22.2508.2508 |
0.33 |
|
| 2016 |
Ou S, Park K, Han J, Kim D, Bazhenova L, Pang Y, Hin HS, Juan O, Son J, Voccia I, Massey D, Kim M, Jänne PA. Abstract CT079: ELUXA 1: Ph II study of BI1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct079 |
0.501 |
|
| 2016 |
Bazhenova L, Mehra R, Nagy T, Cavanna L, Lee J, Han J, Kim HK, Halmos B, Shum M, Schreeder M, Rybkin I, Badin F, Mena R, Jänne PA, Christensen J, et al. Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET) Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw383.93 |
0.507 |
|
| 2016 |
Bazhenova L, Gettinger S, Langer C, Salgia R, Gold K, Rosell R, Shaw A, Weiss G, Haney J, Rivera V, Haluska F, Kerstein D, Camidge D. Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) in a phase 1/2 trial Annals of Oncology. 27: vi418. DOI: 10.1093/Annonc/Mdw383.08 |
0.524 |
|
| 2016 |
Subbiah V, Combest A, Griley-Olsen J, Sharma N, Andrews E, Bobe I, Balkissoon J, Camp A, Masada A, Reitsma D, Bazhenova L. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in pts with advanced solid tumors Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw368.41 |
0.335 |
|
| 2016 |
Graf R, Lu D, Krupa R, Louw J, Dugan L, Jendrisak A, Orr S, Bethel K, Wang Y, Suraneni M, Landers M, Boffa D, Nieva J, Bazhenova L, Salazar M, et al. PD-L1 expression on circulating CD45(-) cells is an independent prognostic factor for overall survival (OS) in patients (Pts) across all stages of treatment-naïve lung cancer in a prospective, multicenter study Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw363.23 |
0.423 |
|
| 2016 |
Drilon A, Marwan F, Fu S, Patel MR, Olszanski AJ, Lockhart AC, Liu SV, Bazhenova L, Seery T, Nikolinakos P, Patel R, Oliver JW, Multani PS, Wang D. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)33024-6 |
0.368 |
|
| 2016 |
Subbiah V, Combest A, Grilley-Olson J, Sharma N, Andrews E, Bobe I, Balkissoon J, Camp A, Masada A, Reitsma D, Bazhenova L. Phase Ib/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine (G) in patients (pts) with advanced solid tumors European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32952-5 |
0.364 |
|
| 2015 |
Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. PMID 26418953 DOI: 10.18632/Oncotarget.5289 |
0.3 |
|
| 2015 |
Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. European Journal of Cancer (Oxford, England : 1990). PMID 26283035 DOI: 10.1016/j.ejca.2015.07.035 |
0.335 |
|
| 2015 |
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, et al. Non-small cell lung cancer, version 6.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 515-24. PMID 25964637 DOI: 10.6004/Jnccn.2015.0071 |
0.386 |
|
| 2015 |
Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R. Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 6: 6029-39. PMID 25760241 DOI: 10.18632/Oncotarget.3472 |
0.462 |
|
| 2015 |
Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics. Cell Cycle (Georgetown, Tex.). 14: 1252-9. PMID 25695927 DOI: 10.1080/15384101.2015.1014149 |
0.419 |
|
| 2015 |
Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ. The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation. American Journal of Physiology. Cell Physiology. 308: C229-36. PMID 25411332 DOI: 10.1152/Ajpcell.00315.2014 |
0.411 |
|
| 2015 |
Das S, Bazhenova L. How long is too long: the safe use of maintenance bevacizumab in advanced-stage NSCLC Lung Cancer Management. 4: 163-168. DOI: 10.2217/Lmt.15.17 |
0.49 |
|
| 2015 |
Bauer TM, Adkins D, Schwartz GK, Werner TL, Alva AS, Hong DS, Carvajal RD, Saleh MN, Bazhenova L, Goel S, Eaton KD, Siegel RD, Wang D, Lauer RC, Neuteboom STC, et al. A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors. Journal of Clinical Oncology. 33: 2575-2575. DOI: 10.1200/Jco.2016.34.15_Suppl.2575 |
0.41 |
|
| 2015 |
Singh VM, Alexiadis V, Watanaskul T, Salas E, Huynh L, Mitchell C, Fauni R, Bazhenova L, Arnold L. Clinical validation and utility of a liquid biopsy for non-small cell lung carcinoma utilizing CTCs and ctDNA to analyze ALK, ROS and EGFR status. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19086 |
0.42 |
|
| 2015 |
Camidge DR, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, Shaw AT, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson TP, Conlan MG, Kerstein D, Haluska FG, et al. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC). Journal of Clinical Oncology. 33: 8062-8062. DOI: 10.1200/Jco.2015.33.15_Suppl.8062 |
0.468 |
|
| 2015 |
Cohen RB, Morgensztern D, Walsh WV, Bazhenova L, Melnyk AM, Beck JT, Nemunaitis JJ, Schreiber TH, Price ML. First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial. Journal of Clinical Oncology. 33: 3077-3077. DOI: 10.1200/Jco.2015.33.15_Suppl.3077 |
0.426 |
|
| 2015 |
Goss GD, Yang JCH, Ahn MJ, Tsai CM, Bazhenova L, Sequist LV, Ramalingam SS, Shepherd FA, Ghiorghiu S, Cantarini M, Mann H, Mitsudomi T, Jänne PA. 3113 AZD9291 in pre-treated patients with T790M positive advanced non-small cell lung cancer (NSCLC): Pooled analysis from two Phase II studies European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31754-3 |
0.52 |
|
| 2015 |
Ahn MJ, Tsai CM, Yang JCH, Shepherd FA, Satouchi M, Kim DW, Bazhenova L, Hirashima T, Rukazenkov Y, Cantarini M, Mann H, Ramalingam SS, Mitsudomi T, Jänne PA, Goss GD. 3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies European Journal of Cancer. 51. DOI: 10.1016/S0959-8049(16)31724-5 |
0.513 |
|
| 2015 |
Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss G, Narasimhan N, Dorer D, Rivera V, Clackson T, Haluska F, Camidge D. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases Lung Cancer. 87: S32. DOI: 10.1016/S0169-5002(15)50080-9 |
0.489 |
|
| 2015 |
Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer European Journal of Cancer. DOI: 10.1016/j.ejca.2015.07.035 |
0.311 |
|
| 2014 |
Gettinger S, Bazhenova L, Salgia R, Langer C, Gold K, Rosell R, Shaw A, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG, Camidge R. 1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv455. PMID 28172024 DOI: 10.1093/Annonc/Mdu349.71 |
0.425 |
|
| 2014 |
Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, Nieva J, Kuhn P. Entropy, complexity, and Markov diagrams for random walk cancer models. Scientific Reports. 4: 7558. PMID 25523357 DOI: 10.1038/Srep07558 |
0.354 |
|
| 2014 |
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, et al. Non-small cell lung cancer, version 1.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1738-61. PMID 25505215 DOI: 10.6004/Jnccn.2014.0176 |
0.351 |
|
| 2014 |
Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5927-36. PMID 25231400 DOI: 10.1158/1078-0432.Ccr-14-0804 |
0.359 |
|
| 2014 |
Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW, Shrager JB, Bethel K, Hoh CK, Bazhenova L, et al. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1111-9. PMID 25157764 DOI: 10.1097/Jto.0000000000000235 |
0.489 |
|
| 2014 |
Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, et al. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. Journal of Neuro-Oncology. 119: 361-8. PMID 24942463 DOI: 10.1007/S11060-014-1486-2 |
0.425 |
|
| 2014 |
Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P. Adrenal metastases in lung cancer: clinical implications of a mathematical model. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 442-6. PMID 24736064 DOI: 10.1097/Jto.0000000000000133 |
0.423 |
|
| 2014 |
Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Therapeutic Advances in Respiratory Disease. 8: 3-12. PMID 24334338 DOI: 10.1177/1753465813512545 |
0.487 |
|
| 2014 |
Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clinical Lung Cancer. 15: 131-5. PMID 24157245 DOI: 10.1016/J.Cllc.2013.08.007 |
0.437 |
|
| 2014 |
Bazhenova L, Giaccone G, Nemunaitis JJ, Juhász E, Ramlau R, Heuvel MMvd, Lal R, Dunlop D, Garon EB, Chu QS, Jain MM, Carrier E, Moses S, Shawler D, Fakhrai H. An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. Journal of Clinical Oncology. 32: 8056-8056. DOI: 10.1200/Jco.2014.32.15_Suppl.8056 |
0.469 |
|
| 2014 |
Heist RS, Aren OR, Mita AC, Polikoff J, Bazhenova L, Lloyd GK, Mikrut W, Reich SD, Spear MA, Huang L. Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8054-8054. DOI: 10.1200/Jco.2014.32.15_Suppl.8054 |
0.409 |
|
| 2014 |
Ali SM, Ou SI, He J, Peled N, Chmielecki J, Pinder MC, Palma NA, Akerley WL, Wang K, Molina JR, Ross JS, Yelensky R, Frampton GM, Bazhenova L, Palmer GA, et al. Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma. Journal of Clinical Oncology. 32: 8049-8049. DOI: 10.1200/Jco.2014.32.15_Suppl.8049 |
0.395 |
|
| 2014 |
Gettinger SN, Bazhenova L, Salgia R, Langer CJ, Gold KA, Rosell R, Shaw AT, Weiss GJ, Narasimhan NI, Dorer DJ, Rivera VM, Clackson T, Haluska FG, Camidge DR. Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8047-8047. DOI: 10.1200/Jco.2014.32.15_Suppl.8047 |
0.431 |
|
| 2014 |
Cohen RB, Nemunaitis J, Gabrail N, Bazhenova L, Schreiber TH, Price M. A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer Journal For Immunotherapy of Cancer. 2: P82. DOI: 10.1186/2051-1426-2-S3-P82 |
0.436 |
|
| 2014 |
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, et al. Non-small cell lung cancer, version 1.2015: Clinical practice guidelines in oncology Jnccn Journal of the National Comprehensive Cancer Network. 12: 1738-1761. |
0.329 |
|
| 2013 |
Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. Plos One. 8: e67733. PMID 23861795 DOI: 10.1371/Journal.Pone.0067733 |
0.429 |
|
| 2013 |
Randall JM, Bharne AA, Bazhenova LA. Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer. Journal of Thoracic Disease. 5: E53-7. PMID 23585959 DOI: 10.3978/j.issn.2072-1439.2012.06.12 |
0.406 |
|
| 2013 |
Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Norton L, Kuhn P. Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model. Cancer Research. 73: 2760-9. PMID 23447576 DOI: 10.1158/0008-5472.Can-12-4488 |
0.337 |
|
| 2013 |
Randall JM, Voth R, Burnett E, Bazhenova L, Bardwell WA. Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 21: 1503-7. PMID 23325092 DOI: 10.1007/S00520-012-1712-4 |
0.307 |
|
| 2013 |
Carlsson A, Bazhenova L, Kolatkar A, Luttgen M, Bethel K, Nieva JJ, Kuhn P. Dynamic changes in circulating tumor cell levels as a prognostic marker in stage IV non-small cell lung cancer. Journal of Clinical Oncology. 31: 8109-8109. DOI: 10.1200/Jco.2013.31.15_Suppl.8109 |
0.43 |
|
| 2013 |
Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, Narasimhan NI, Dorer DJ, Rivera VM, Zhang J, Clackson T, Haluska FG, Gettinger SN. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. Journal of Clinical Oncology. 31: 8031-8031. DOI: 10.1200/Jco.2013.31.15_Suppl.8031 |
0.432 |
|
| 2013 |
Sandhu AP, Lau SKM, Rahn D, Nath SK, Kim D, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. 51P Stereotactic Body Radiation Therapy In Octogenarians With Early Stage Lung Cancer Lung Cancer. 80. DOI: 10.1016/S0169-5002(13)70272-1 |
0.379 |
|
| 2012 |
Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Physical Biology. 9: 016005. PMID 22307026 DOI: 10.1088/1478-3967/9/1/016005 |
0.473 |
|
| 2012 |
Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Physical Biology. 9: 016004. PMID 22306961 DOI: 10.1088/1478-3975/9/1/016004 |
0.464 |
|
| 2012 |
Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Physical Biology. 9: 016003. PMID 22306768 DOI: 10.1088/1478-3975/9/1/016003 |
0.365 |
|
| 2012 |
Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Physical Biology. 9: 016001. PMID 22306705 DOI: 10.1088/1478-3975/9/1/016001 |
0.364 |
|
| 2012 |
Bazhenova L, Nieva JJ, Kolatkar A, Luttgen M, Marinucci D, Bethel K, Kuhn P. Performance of the high-definition circulating tumor cells (HD-CTC) assay in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: e21074-e21074. DOI: 10.1200/Jco.2012.30.15_Suppl.E21074 |
0.435 |
|
| 2012 |
Hassan R, Jahan TM, Kindler HL, Bazhenova L, Reck M, Pastan I, Ellis A, Fatato PM, Heyburn J, Schweizer C, Parno J, Wallin B. Amatuximab, a chimeric monoclonal antibody to mesothelin, in combination with pemetrexed and cisplatin in patients with unresectable pleural mesothelioma: Results of a multicenter phase II clinical trial. Journal of Clinical Oncology. 30: 7030-7030. DOI: 10.1200/Jco.2012.30.15_Suppl.7030 |
0.394 |
|
| 2012 |
Scott BJ, Feely H, Brown T, Vugt VV, Kim R, Fanta PT, Bazhenova L, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for the treatment of leptomeningeal metastasis from solid tumors. Journal of Clinical Oncology. 30: 2052-2052. DOI: 10.1200/Jco.2012.30.15_Suppl.2052 |
0.362 |
|
| 2012 |
Bazhenova L, Carrier E, Shawler D, Fakhrai H. Abstract 5367: Long-term survival in a phase II atudy of belagenpumatucel-L (TGF-β antisense modified tumor cell vaccine) in non-small cell lung cancer (NSCLC). Cancer Research. 72: 5367-5367. DOI: 10.1158/1538-7445.Am2012-5367 |
0.426 |
|
| 2012 |
Kuhn P, Keu KV, Nair VS, Luttgen M, Maestas S, Bethel K, Souder K, Vasanawala M, Kuschner W, Iagaru AH, Hoh C, Nieva J, Bazhenova L, Gambhir SS. Abstract 2369: Correlating circulating tumor cells with18F-FDG positron emission tomography (PET) uptake in patients with treatment naïve non-small cell lung cancer: A pilot study Cancer Research. 72: 2369-2369. DOI: 10.1158/1538-7445.Am2012-2369 |
0.431 |
|
| 2012 |
Reck M, Hassan R, Jahan T, Kindler HL, Bazhenova L, Fatato P, Heyburn JW, Parno J, Maltzman JD, Wallin B. A Multi-Center Phase II Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody Amatuximab in Combination with Chemotherapy for Frontline Therapy of Malignant Pleural Mesothelioma: Updated Clinical Outcomes and Correlative Studies Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)34090-4 |
0.381 |
|
| 2012 |
Gettinger S, Weiss G, Salgia R, Bazhenova L, Narasimhan N, Dorer D, Rivera V, Zhang J, Clackson T, Haluska F, Shaw A, Camidge D. A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies Annals of Oncology. 23: ix152. DOI: 10.1016/S0923-7534(20)33005-2 |
0.453 |
|
| 2011 |
Wendell M, Bazhenova L, Morgan A, Boisot S, Marinucci D, Luttgen M, Nieva JJ, Kuhn P, Bethel K. Circulating tumor cells (CTC) in mesothelioma and its cytomorphological and immunohistochemical correlation with the primary tumor specimens. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21170. PMID 28022737 DOI: 10.1200/Jco.2011.29.15_Suppl.E21170 |
0.356 |
|
| 2011 |
Sandhu AP, Gill BS, Kim D, Bazhenova L, Read WL, Nobiensky PD. Stereotactic body radiotherapy (SBRT) for effective palliation of lung tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e19632. PMID 28021770 DOI: 10.1200/Jco.2011.29.15_Suppl.E19632 |
0.455 |
|
| 2011 |
Randall JM, Bazhenova L, White M, Bharne AA, Shimabukuro KA, Matusov Y, Messer K, Lowery A, Loscalzo M, Clark K, Bardwell W. Prevalence and correlates of suicidal ideation among outpatients at a comprehensive cancer center. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9044. PMID 28021643 DOI: 10.1200/Jco.2011.29.15_Suppl.9044 |
0.32 |
|
| 2011 |
Nath SK, Sandhu AP, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster M, Bazhenova L, Song WY, Mundt AJ. Locoregional and distant failure following image-guided stereotactic body radiation for early-stage primary lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 99: 12-7. PMID 21429608 DOI: 10.1016/J.Radonc.2011.02.006 |
0.368 |
|
| 2011 |
Ahmad E, Sandhu AP, Fuster MM, Messer K, Pu M, Nobiensky P, Bazhenova L, Seagren S. Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients. American Journal of Clinical Oncology. 34: 254-8. PMID 20562588 DOI: 10.1016/J.Ijrobp.2008.06.1412 |
0.456 |
|
| 2011 |
Gill B, Sandhu A, Kim D, Bazhenova L, Nobiensky P, Read W. Stereotactic Body Radiotherapy (SBRT) for Effective Palliation of Lung Tumors Chest. 140: 955A. DOI: 10.1378/Chest.1115479 |
0.382 |
|
| 2011 |
Souder KN, Matusov Y, Helsten TL, Fanta PT, Hiner KL, Brechlin JI, Bazhenova L. Clinical trial accrual patterns at a single cancer center: Preliminary results. Journal of Clinical Oncology. 29. DOI: 10.1200/Jco.2011.29.15_Suppl.E16638 |
0.362 |
|
| 2011 |
Wendel M, Bazhenova L, Nieva J, Bethel K, Marrinucci D, Cho EH, Yoshioka C, Luttgen M, Uson L, Metzner T, Kolatkar A, Torrey M, Kuhn P. Abstract 4151: High definition circulating tumor cells in patients with non-small cell lung cancer Cancer Research. 71: 4151-4151. DOI: 10.1158/1538-7445.Am2011-4151 |
0.488 |
|
| 2010 |
Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, Bang YJ, Kwak EL, Shaw AT, Salgia R, Maki RG, Clark JW, Wilner KD, Iafrate AJ. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 2044-6. PMID 21102269 DOI: 10.1097/Jto.0B013E318200F9Ff |
0.485 |
|
| 2010 |
Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2450-7. PMID 20332327 DOI: 10.1158/1078-0432.Ccr-09-1920 |
0.432 |
|
| 2010 |
Bharne AA, Mills P, Bardwell W, White M, Messer K, Bazhenova L. Biochemical correlates of fatigue in patients at a comprehensive cancer center. Journal of Clinical Oncology. 28: 9162-9162. DOI: 10.1200/Jco.2010.28.15_Suppl.9162 |
0.361 |
|
| 2010 |
Mita AC, Heist RS, Aren O, Mainwaring PN, Bazhenova L, Gadgeel SM, Blum RH, Polikoff J, Biswas J, Spear MA. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7592-7592. DOI: 10.1200/Jco.2010.28.15_Suppl.7592 |
0.457 |
|
| 2009 |
Luttgen MS, Marrinucci D, Lazar D, Malchiodi M, Clark P, Huynh E, Bethel K, Bazhenova L, Nieva J, Kuhn P. Circulating tumor cells monitored over time in lung cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11025. PMID 27963968 DOI: 10.1200/Jco.2009.27.15_Suppl.11025 |
0.488 |
|
| 2009 |
Bharne AA, Shimabukuro KA, Vu PH, White MM, Mills PJ, Bardwell WA, Messer K, Bazhenova L. Prevalence and correlates of fatigue among patients at a comprehensive cancer center. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9608. PMID 27963841 DOI: 10.1200/Jco.2009.27.15_Suppl.9608 |
0.358 |
|
| 2009 |
Sandhu AP, Messer K, Fuster MM, Ahmad E, Pu M, Bazhenova L, Rose M, Seagren S. Definitive radiation therapy for stage I non-small-cell lung carcinoma: institutional experience with contemporary conformal planning. Clinical Lung Cancer. 10: 433-7. PMID 19900862 DOI: 10.3816/CLC.2009.n.081 |
0.307 |
|
| 2009 |
Page LJ, Suk JY, Bazhenova L, Fleming SM, Wood M, Jiang Y, Guo LT, Mizisin AP, Kisilevsky R, Shelton GD, Balch WE, Kelly JW. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proceedings of the National Academy of Sciences of the United States of America. 106: 11125-30. PMID 19549824 DOI: 10.1073/Pnas.0811753106 |
0.403 |
|
| 2009 |
Heist R, Aren O, Millward M, Mainwaring P, Mita A, Mita M, Bazhenova L, Blum R, Polikoff J, Gadgeel S, Deshmukh C, Llyod GK, Reich S, Spear MA. Abstract C30: Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI‐2358) combined with docetaxel in patients with non‐small cell lung cancer (NSCLC) Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C30 |
0.457 |
|
| 2007 |
Peterson MR, Piao Z, Bazhenova LA, Weidner N, Yi ES. Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 15: 242-7. PMID 17721266 DOI: 10.1097/PAI.0b013e31802d1590 |
0.314 |
|
| Show low-probability matches. |